Provided by Daphne Lainson
Daphne Lainson has specialized in helping clients to secure patent protection for chemical, pharmaceutical and biotechnology related inventions, and advising them on regulatory law, for almost two decades. The world’s top innovators of pharmaceuticals and biologics rely on Daphne’s strategic advice and counsel across the life cycle of a drug, including during pre-clinical and clinical development through to marketing and loss of exclusivity. What sets her apart is her deep expertise in patent procurement and the various issues that can arise relating to patent linkage under the Patented Medicines (Notice of Compliance) Regulations, supplementary protection under the Certificate of Supplementary Protection Regulations, and regulatory data exclusivity under the Food and Drug Regulations, in addition to protection under the Certificates of Supplementary Protection Regulations. She is also an expert in market access issues and pricing for patented medicines under the jurisdiction of Patented Medicine Prices Review Board (PMPRB). Daphne is recognized as a leading lawyer in: LMG Life Sciences; Managing Intellectual Property’s IP Stars Handbook: Patents; IAM’s Patent 1000, Strategy 300, and Global Leaders; WIPR Leaders and Women in IP; Who’s Who Legal: Canada and Patents; Euromoney's Expert Guides: Women in Business Law, Patents, and Life Sciences; Lexpert and Best Lawyers.
Chair of Smart & Biggar Daphne Lainson possesses significant experience advising major pharmaceutical clients on patent filing, strategy and portfolio management. She is based in Ottawa.
"She delivers a succinct and understandable work product."